Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study investigated the efficacy and safety of once-daily liraglutide 1.2 mg versus placebo as add-on to insulin treatment in normal-weight patients with poorly controlled type 1 diabetes. RESEARCH DESIGN AND METHODS: In a randomized (1:1), double-blind, placebo-controlled design, 40 patients with type 1 diabetes (HbA1c ≥8% [64 mmol/mol]) received once-daily liraglutide 1.2 mg or placebo for 12 weeks. Continuous glucose monitoring was performed before and at the end of treatment. The primary end point was change in HbA1c. Secondary end points included change in insulin dose, weight, glycemic excursions, heart rate, and blood pressure. RESULTS: Baseline HbA1c was similar in the liraglutide and placebo group (8.8 ± 0.2 and 8.7 ± 0.1% [72.5 ± 2.2 and 71.8 ± 1.5 mmol/mol]). Change in HbA1c from baseline was −0.6 ± 0.2% (−6.22 ± 1.71 mmol/mol) with liraglutide and −0.5 ± 0.2% (−5.56 ± 1.67 mmol/mol) with placebo (P = 0.62). Variation in glycemic excursions did not change in either group. Change in body weight was −3.13 ± 0.58 and +1.12 ± 0.42 kg (P < 0.0001) with liraglutide and placebo, respectively. The bolus insulin dose decreased in liraglutide-treated patients and did not change with placebo treatment (4.0 ± 1.3 vs. 0.0 ± 1.0 IU, P = 0.02). Heart rate increased within the liraglutide group (P = 0.04) but not compared with placebo, whereas mean systolic blood pressure decreased compared with placebo (between-group difference 3.21 mmHg [95% CI −8.31 to 1.90], P = 0.04). Liraglutide was more frequently associated with gastrointestinal adverse effects. The incidence of hypoglycemia did not differ between groups. CONCLUSIONS: Liraglutide significantly reduces body weight and insulin requirements but has no additional effect on HbA1c in normal-weight patients with type 1 diabetes inadequately controlled on insulin alone.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“While several studies included in their analysis did not find significant changes in HbA1c, they did find a reduction in insulin requirements.15,35,36”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [35]
In the citing paper
“ketoacidosis at lower glucose levels, so called 'euglycaemic ketoacidosis', has been reported in 2-3% of patients with T1DM taking SGLT2 inhibitors.804”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [804]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 1×
“requiring assistance of another person to actively administer carbohydrates, glucagon, or take other corrective actions with or without measurement of blood glucose levels (33).”
BackgroundPathologic anatomy of the pancreas in juvenile diabetes mellitus
Gepts, W. (1965) · Diabetes · doi:10.2337/diab.14.10.619 · Cited by 1,345
Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., Madsen, J., Rasmussen, M. F., & Lean, M. E. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61375-1 · Cited by 1,163
Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868
Self-citationRisk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration
UK Hypoglycaemia Study Group (2007) · Diabetologia · doi:10.1007/s00125-007-0599-y · Cited by 825
Gold, A. E., Macleod, K. M., & Frier, B. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.7.697 · Cited by 810 · cited 2×
“hypoglycemic awareness status was determined by the Gold (25), Clarke (26)”
MethodClarke, W. L., Cox, D. J., Gonder-Frederick, L. A., Julian, D., Schlundt, D., & Polonsky, W. (1995) · Diabetes Care · doi:10.2337/diacare.18.4.517 · Cited by 651
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599 · cited 1×
“Both defects contribute to abnormal glucose metabolism (5).”
BackgroundThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Self-citationBuse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-2-201101180-00300 · Cited by 506
Hill, N. R., Oliver, N. S., Choudhary, P., Levy, J. C., Hindmarsh, P., & Matthews, D. R. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0247 · Cited by 362
A Novel Approach to Continuous Glucose Analysis Utilizing Glycemic Variation
McDonnell, C. M., Donath, S. M., Vidmar, S. I., Werther, G. A., & Cameron, F. J. (2005) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2005.7.253 · Cited by 358
Implementation of Treatment Protocols in the Diabetes Control and Complications Trial
Diabetes Control and Complications Trial Research Group (1995) · Diabetes Care · doi:10.2337/diacare.18.3.361 · Cited by 283
Marso, S. P., Poulter, N. R., Nissen, S. E., Nauck, M. A., Zinman, B., Daniels, G. H., Pocock, S., Steinberg, W. M., Bergenstal, R. M., Mann, J. F. E., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.07.012 · Cited by 245 · cited 2×
“The clinical significance of these cardiovascular effects is unknown; consequently, it is currently an area of active research in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) (38), Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL; ClinicalTrials.gov…”
BackgroundRecall of severe hypoglycaemia and self‐estimated state of awareness in type 1 diabetes
Pedersen‐Bjergaard, U., Pramming, S., & Thorsteinsson, B. (2003) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.377 · Cited by 240
Self-citationFailure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM
Dinneen, S., Alzaid, A., Turk, D., & Rizza, R. (1995) · Diabetologia · doi:10.1007/bf00400639 · Cited by 190
Incretin hormones and the satiation signal
Holst, J. J. (2013) · International Journal of Obesity · doi:10.1038/ijo.2012.208 · Cited by 188
Self-citationKielgast, U., Krarup, T., Holst, J. J., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-0096 · Cited by 165
Self-citationMathieu, C., Rodbard, H. W., Cariou, B., Handelsman, Y., Philis‐Tsimikas, A., Ocampo Francisco, A. M., Rana, A., Zinman, B., & on behalf of the BEGIN: VICTOZA ADD‐ON (NN1250‐3948) study group (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12262 · Cited by 158
Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM
Dupre, J., Behme, M. T., Hramiak, I. M., McFarlane, P., Williamson, M. P., Zabel, P., & McDonald, T. J. (1995) · Diabetes · doi:10.2337/diab.44.6.626 · Cited by 151 · cited 1×
“The current study was inspired by previous clinical and physiological studies suggesting that GLP-1 and GLP-1RAs decrease postprandial g lucose and glucagon levels, slow the gastric emptying rate, and decrease meal-related insulin requirements in patients with type 1 diabetes, regardless of residual b-cell function (1…”
ResultHeller, S. R., Amiel, S. A., & Mansell, P. (1999) · Diabetes Care · doi:10.2337/diacare.22.10.1607 · Cited by 149
Ferdinand, K. C., White, W. B., Calhoun, D. A., Lonn, E. M., Sager, P. T., Brunelle, R., Jiang, H. H., Threlkeld, R. J., Robertson, K. E., & Geiger, M. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.114.03062 · Cited by 145
Exenatide Therapy in Obese Patients With Type 2 Diabetes Mellitus Treated with Insulin
Viswanathan, P., Chaudhuri, A., Bhatia, R., Al-Atrash, F., Mohanty, P., & Dandona, P. (2007) · Endocrine Practice · doi:10.4158/ep.13.5.444 · Cited by 142
Kielgast, U., Holst, J. J., & Madsbad, S. (2011) · Diabetes · doi:10.2337/db10-1790 · Cited by 137
Self-citationRother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133
Liraglutide as additional treatment for type 1 diabetes
Varanasi, A., Bellini, N., Rawal, D., Vora, M., Makdissi, A., Dhindsa, S., Chaudhuri, A., & Dandona, P. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0330 · Cited by 129 · cited 2×
“have suggested that adding a GLP-1RA to insulin improves glycemic control compared with insulin treatment alone (19,21,22).”
BackgroundResultGreenbaum, C. J., Prigeon, R. L., & D’Alessio, D. A. (2002) · Diabetes · doi:10.2337/diabetes.51.4.951 · Cited by 119
Kumar, K. V. S. H., Shaikh, A., & Prusty, P. (2013) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.01.020 · Cited by 102
Liraglutide as Additional Treatment to Insulin in Obese Patients with Type 1 Diabetes Mellitus
Kuhadiya, N. D., Malik, R., Bellini, N. J., Patterson, J. L., Traina, A. N., Makdissi, A., & Dandona, P. (2013) · Endocrine Practice · doi:10.4158/ep13065.or · Cited by 81 · cited 2×
“have suggested that adding a GLP-1RA to insulin improves glycemic control compared with insulin treatment alone (19,21,22).”
BackgroundResultExenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes
Sarkar, G., Alattar, M., Brown, R. J., Quon, M. J., Harlan, D. M., & Rother, K. I. (2014) · Diabetes Care · doi:10.2337/dc13-1473 · Cited by 74
Davies, M. J., Kela, R., & Khunti, K. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01330.x · Cited by 66
Li, C.-J., Li, J., Zhang, Q.-M., Lv, L., Chen, R., Lv, C.-F., Yu, P., & Yu, D.-M. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-142 · Cited by 64
Type 1 Diabetes Treatment beyond Insulin: Role of GLP-1 Analogs
Harrison, L. B., Mora, P. F., Clark, G. O., & Lingvay, I. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318279b7d6 · Cited by 46
MADSBAD, S., SAUERBREY, N., MØLLER‐JENSEN, B., KRARUP, T., & KUHL, C. (1987) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1987.tb09931.x · Cited by 20 · cited 1×
“defined as a stimulated C-peptide ,60 pmol/L (28,29).”
BackgroundSelf-citationGjessing, H. J., Reinholdt, B., FABER, O. K., & Pedersen, O. B. (1991) · European Journal of Endocrinology · doi:10.1530/acta.0.1240556 · Cited by 17 · cited 1×
“defined as a stimulated C-peptide ,60 pmol/L (28,29).”
BackgroundDejgaard, T. F., Knop, F. K., Tarnow, L., Frandsen, C. S., Hansen, T. S., Almdal, T., Holst, J. J., Madsbad, S., & Andersen, H. U. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-007791 · Cited by 17 · cited 1×
“The current study does not provide data on fasting and postprandial glucagon levels, but this is currently an area of active research in our and other groups (39).”
BackgroundSelf-citation
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
“lower insulin dose in liraglutide-treated subjects, as well as difficulties in accurately adjusting bolus insulin and food intake (6,9).”
BackgroundAhrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262
New frontiers in the treatment of type 1 diabetes
Warshauer, J. T., Bluestone, J. A., & Anderson, M. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2019.11.017 · Cited by 259
Alfaris, N., Waldrop, S., Johnson, V., Boaventura, B., Kendrick, K., & Stanford, F. C. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102782 · Cited by 224
“15,35,36 Furthermore, differences in hypo-glycemic events were not substantial or reduced in combination treatment, suggesting that combination treatment does not increase the risk of hypoglycemia.”
Background
Metadata
- Authors
- Frandsen, C. S., Dejgaard, T. F., Holst, J. J., Andersen, H. U., Thorsteinsson, B., & Madsbad, S.
- Affiliations
- University of Copenhagen (DK)
- Steno Diabetes Center, Gentofte, Denmark
- Corresponding author
- Frandsen, Christian S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-10-20
- Volume
- 38
- Issue
- 12
- Pages
- 2250-2257
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1806569300
- Cited by
- 103
- References
- 40
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 8 · 2023: 6 · 2022: 9 · 2021: 8 · 2020: 9 · 2019: 7 · 2018: 15 · 2017: 8 · 2016: 16 · 2015: 2
- FWCI
- 11.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Funders
- The Danish School of Metabolism and Endocrinology
- Novo Nordisk Foundation, Center for Basic Metabolic Research
- The Research Foundation at Hvidovre University Hospital
- The Beckett Foundation,
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Keywords
- liraglutide, type 1 diabetes, insulin add-on therapy, normal-weight patients, glycemic control, HbA1c, glycemic excursions, weight loss, heart rate, blood pressure, gastrointestinal adverse effects, GLP-1 receptor agonists, continuous glucose monitoring, drug safety and tolerability, uncontrolled diabetes
- MeSH terms
- Liraglutide, Adult, Body Weight, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypoglycemic Agents, Insulin, Male, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.